Icatibant

Firazyr, ICATIBANT, SAJAZIR

Bradykinin B2 Receptor Antagonist

NADAC/unit N/A

No Shortage Tier 1: 28.3% PA Req: 158.7% 8 Manufacturers 8 ANDAs

SAJAZIR (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Covered Lives

Generic Manufacturers

ALEMBIC PHARMACEUTICALS LTDCIPLA LTDEUGIA PHARMA SPECIALITIES LTDFRESENIUS KABI USA LLCJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTDNANG KUANG PHARMACEUTICAL CO LTDTAKEDA PHARMACEUTICALS USA INCTEVA PHARMACEUTICALS USA INCWILSHIRE PHARMACEUTICALS INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Icatibant drfinder.aiFind doctors who prescribe Icatibant rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Icatibant

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.